Cargando…

Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?

Background: HBV is the leading global cause of cirrhosis and primary liver cancer. However, the UK HBV population has not been well characterised, and estimates of UK HBV prevalence and/or incidence vary widely between sources. We aimed to i) extract and summarise existing national HBV prevalence es...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Cori, Wang, Tingyan, Burrow, Rebekah, Mandal, Sema, Hippisley-Cox, Julia, Barnes, Eleanor, Matthews, Philippa C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975428/
https://www.ncbi.nlm.nih.gov/pubmed/36874587
http://dx.doi.org/10.12688/wellcomeopenres.17941.2
_version_ 1784898871658283008
author Campbell, Cori
Wang, Tingyan
Burrow, Rebekah
Mandal, Sema
Hippisley-Cox, Julia
Barnes, Eleanor
Matthews, Philippa C
author_facet Campbell, Cori
Wang, Tingyan
Burrow, Rebekah
Mandal, Sema
Hippisley-Cox, Julia
Barnes, Eleanor
Matthews, Philippa C
author_sort Campbell, Cori
collection PubMed
description Background: HBV is the leading global cause of cirrhosis and primary liver cancer. However, the UK HBV population has not been well characterised, and estimates of UK HBV prevalence and/or incidence vary widely between sources. We aimed to i) extract and summarise existing national HBV prevalence estimates, ii) add a new estimate based on primary care data, and; iii) critique data sources from which estimates were derived. Methods: We undertook a narrative review, searching for national estimates of CHB case numbers in the UK (incorporating incidence, prevalence and/or test positivity data) across a range of overlapping sources, including governmental body reports, publications from independent bodies (including medical charities and non-governmental organisations) and articles in peer-reviewed scientific journals.  An alternative proxy for population prevalence was obtained via the UK antenatal screening programme which achieves over 95% coverage of pregnant women. We also searched for diagnoses of HBV in the QResearch primary care database based on laboratory tests and standardised coding. Results: We identified six CHB case number estimates, of which three reported information concerning population subgroups, including number of infected individuals across age, sex and ethnicity categories. Estimates among sources reporting prevalence varied from 0.27% to 0.73%, congruent with an estimated antenatal CHB prevalence of <0.5%. Our estimate, based on QResearch data, suggests a population prevalence of ~0.05%, reflecting a substantial underestimation based on primary care records. Discussion: Estimates varied by sources of error, bias and missingness, data linkage, and “blind spots” in HBV diagnoses testing/registration. The UK HBV burden is likely to be concentrated in vulnerable populations who may not be well represented in existing datasets including those experiencing socioeconomic deprivation and/or homelessness, ethnic minorities and people born in high-prevalence countries. This could lead to under- or over-estimation of population prevalence estimation. Multi-agency collaboration is required to fill evidence gaps.
format Online
Article
Text
id pubmed-9975428
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-99754282023-03-02 Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing? Campbell, Cori Wang, Tingyan Burrow, Rebekah Mandal, Sema Hippisley-Cox, Julia Barnes, Eleanor Matthews, Philippa C Wellcome Open Res Research Note Background: HBV is the leading global cause of cirrhosis and primary liver cancer. However, the UK HBV population has not been well characterised, and estimates of UK HBV prevalence and/or incidence vary widely between sources. We aimed to i) extract and summarise existing national HBV prevalence estimates, ii) add a new estimate based on primary care data, and; iii) critique data sources from which estimates were derived. Methods: We undertook a narrative review, searching for national estimates of CHB case numbers in the UK (incorporating incidence, prevalence and/or test positivity data) across a range of overlapping sources, including governmental body reports, publications from independent bodies (including medical charities and non-governmental organisations) and articles in peer-reviewed scientific journals.  An alternative proxy for population prevalence was obtained via the UK antenatal screening programme which achieves over 95% coverage of pregnant women. We also searched for diagnoses of HBV in the QResearch primary care database based on laboratory tests and standardised coding. Results: We identified six CHB case number estimates, of which three reported information concerning population subgroups, including number of infected individuals across age, sex and ethnicity categories. Estimates among sources reporting prevalence varied from 0.27% to 0.73%, congruent with an estimated antenatal CHB prevalence of <0.5%. Our estimate, based on QResearch data, suggests a population prevalence of ~0.05%, reflecting a substantial underestimation based on primary care records. Discussion: Estimates varied by sources of error, bias and missingness, data linkage, and “blind spots” in HBV diagnoses testing/registration. The UK HBV burden is likely to be concentrated in vulnerable populations who may not be well represented in existing datasets including those experiencing socioeconomic deprivation and/or homelessness, ethnic minorities and people born in high-prevalence countries. This could lead to under- or over-estimation of population prevalence estimation. Multi-agency collaboration is required to fill evidence gaps. F1000 Research Limited 2023-03-09 /pmc/articles/PMC9975428/ /pubmed/36874587 http://dx.doi.org/10.12688/wellcomeopenres.17941.2 Text en Copyright: © 2023 Campbell C et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Note
Campbell, Cori
Wang, Tingyan
Burrow, Rebekah
Mandal, Sema
Hippisley-Cox, Julia
Barnes, Eleanor
Matthews, Philippa C
Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?
title Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?
title_full Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?
title_fullStr Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?
title_full_unstemmed Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?
title_short Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?
title_sort estimating the epidemiology of chronic hepatitis b virus (hbv) infection in the uk: what do we know and what are we missing?
topic Research Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975428/
https://www.ncbi.nlm.nih.gov/pubmed/36874587
http://dx.doi.org/10.12688/wellcomeopenres.17941.2
work_keys_str_mv AT campbellcori estimatingtheepidemiologyofchronichepatitisbvirushbvinfectionintheukwhatdoweknowandwhatarewemissing
AT wangtingyan estimatingtheepidemiologyofchronichepatitisbvirushbvinfectionintheukwhatdoweknowandwhatarewemissing
AT burrowrebekah estimatingtheepidemiologyofchronichepatitisbvirushbvinfectionintheukwhatdoweknowandwhatarewemissing
AT mandalsema estimatingtheepidemiologyofchronichepatitisbvirushbvinfectionintheukwhatdoweknowandwhatarewemissing
AT hippisleycoxjulia estimatingtheepidemiologyofchronichepatitisbvirushbvinfectionintheukwhatdoweknowandwhatarewemissing
AT barneseleanor estimatingtheepidemiologyofchronichepatitisbvirushbvinfectionintheukwhatdoweknowandwhatarewemissing
AT matthewsphilippac estimatingtheepidemiologyofchronichepatitisbvirushbvinfectionintheukwhatdoweknowandwhatarewemissing